[go: up one dir, main page]

CL2021000008A1 - Uso de un heparinoide para el tratamiento del cáncer (divisional de la solicitud n° 201403017) - Google Patents

Uso de un heparinoide para el tratamiento del cáncer (divisional de la solicitud n° 201403017)

Info

Publication number
CL2021000008A1
CL2021000008A1 CL2021000008A CL2021000008A CL2021000008A1 CL 2021000008 A1 CL2021000008 A1 CL 2021000008A1 CL 2021000008 A CL2021000008 A CL 2021000008A CL 2021000008 A CL2021000008 A CL 2021000008A CL 2021000008 A1 CL2021000008 A1 CL 2021000008A1
Authority
CL
Chile
Prior art keywords
heparinoid
cancer treatment
divisional application
divisional
cancer
Prior art date
Application number
CL2021000008A
Other languages
English (en)
Inventor
Stephen Marcus
Original Assignee
Cantex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cantex Pharmaceuticals Inc filed Critical Cantex Pharmaceuticals Inc
Publication of CL2021000008A1 publication Critical patent/CL2021000008A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pathology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CL2021000008A 2012-05-09 2021-01-04 Uso de un heparinoide para el tratamiento del cáncer (divisional de la solicitud n° 201403017) CL2021000008A1 (es)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201261644623P 2012-05-09 2012-05-09
US201261644556P 2012-05-09 2012-05-09
US201261648043P 2012-05-16 2012-05-16
US201261653362P 2012-05-30 2012-05-30
US201261664611P 2012-06-26 2012-06-26
US201261668709P 2012-07-06 2012-07-06
US201261678053P 2012-07-31 2012-07-31
US201261702207P 2012-09-17 2012-09-17
US201261724836P 2012-11-09 2012-11-09

Publications (1)

Publication Number Publication Date
CL2021000008A1 true CL2021000008A1 (es) 2021-06-11

Family

ID=49549076

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2014003017A CL2014003017A1 (es) 2012-05-09 2014-11-07 Uso de un heparinoide interactuando con pf4 para tratar efecto mielodepresivo
CL2021000008A CL2021000008A1 (es) 2012-05-09 2021-01-04 Uso de un heparinoide para el tratamiento del cáncer (divisional de la solicitud n° 201403017)

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CL2014003017A CL2014003017A1 (es) 2012-05-09 2014-11-07 Uso de un heparinoide interactuando con pf4 para tratar efecto mielodepresivo

Country Status (21)

Country Link
US (6) US9271999B2 (es)
EP (2) EP3785720A1 (es)
JP (3) JP6177885B2 (es)
KR (2) KR102452803B1 (es)
CN (3) CN113521093A (es)
AU (1) AU2013260101B2 (es)
BR (1) BR112014028094B1 (es)
CA (2) CA3122808A1 (es)
CL (2) CL2014003017A1 (es)
DK (1) DK2846809T3 (es)
EA (1) EA029382B1 (es)
ES (1) ES2848050T3 (es)
HK (1) HK1207574A1 (es)
HU (1) HUE053247T2 (es)
IL (1) IL235593B (es)
LT (1) LT2846809T (es)
MX (2) MX370567B (es)
PL (1) PL2846809T3 (es)
PT (1) PT2846809T (es)
SG (3) SG10201603059YA (es)
WO (1) WO2013169355A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014028094B1 (pt) 2012-05-09 2022-03-03 Cantex Pharmaceuticals, Inc Uso de um heparinoide interagindo com fator de plaqueta 4
CA2928585A1 (en) * 2013-10-22 2015-04-30 Cantex Pharmaceuticals, Inc. Methods of treating and preventing radiation damage
US20170096549A1 (en) 2014-03-17 2017-04-06 Cantex Pharmaceuticals, Inc. Multivalent cation formulations of partially desulfated heparins
WO2016133910A1 (en) * 2015-02-17 2016-08-25 Cantex Pharmaceuticals, Inc. Treatment of cancers and hematopoietic stem cell disorders privileged by cxcl12-cxcr4 interaction
BR112017018954A2 (pt) 2015-03-06 2018-05-15 Beyondspring Pharmaceuticals, Inc. uso de forma mutante de proteína ras e método para tratar câncer
BR112018000229A2 (pt) 2015-07-13 2018-09-04 Beyondspring Pharmaceuticals Inc composições de plinabulina
US10912748B2 (en) 2016-02-08 2021-02-09 Beyondspring Pharmaceuticals, Inc. Compositions containing tucaresol or its analogs
IL263439B1 (en) 2016-06-06 2025-02-01 Beyondspring Pharmaceuticals Inc Composition and method for reducing neutropenia
EP3565812B1 (en) 2017-01-06 2023-12-27 Beyondspring Pharmaceuticals, Inc. Tubulin binding compounds and therapeutic use thereof
CA3052190A1 (en) 2017-02-01 2018-08-09 Beyondspring Pharmaceuticals, Inc. Method of reducing neutropenia
CN107569486A (zh) * 2017-08-23 2018-01-12 北京京佑奇康生物科技有限公司 孟鲁司特钠治疗血小板减少症的新用途
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
US11786523B2 (en) 2018-01-24 2023-10-17 Beyondspring Pharmaceuticals, Inc. Composition and method for reducing thrombocytopenia
WO2019195658A1 (en) 2018-04-05 2019-10-10 Dana-Farber Cancer Institute, Inc. Sting levels as a biomarker for cancer immunotherapy
WO2022015794A1 (en) 2020-07-14 2022-01-20 Optimvia, Llc Methods for synthesizing non-anticoagulant heparan sulfate
EP3914281A1 (en) * 2019-01-25 2021-12-01 Janssen Pharmaceutica NV Methods of enhancing protection against organ and vascular injury, hematopoietic recovery and survival in response to total body radiation/chemical exposure
US20220169668A1 (en) 2019-04-17 2022-06-02 Compass Pathfinder Limited Methods of treating neurocognitive disorders, chronic pain and reducing inflammation
WO2021041532A1 (en) * 2019-08-26 2021-03-04 Dana-Farber Cancer Institute, Inc. Use of heparin to promote type 1 interferon signaling
WO2021095840A1 (en) * 2019-11-13 2021-05-20 Taiho Pharmaceutical Co., Ltd. METHODS OF TREATING LSD1-RELATED DISEASES and Disorders WITH LSD1 INHIBITORS
WO2021207697A1 (en) 2020-04-10 2021-10-14 Cantex Pharmaceuticals, Inc. Treatment of acute lung injury
KR20230058289A (ko) 2021-10-21 2023-05-03 숙명여자대학교산학협력단 혈액암 치료를 위한 글리세오플빈 병용요법

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2374910A1 (fr) 1976-10-23 1978-07-21 Choay Sa Preparation a base d'heparine, comprenant des liposomes, procede pour l'obtenir et medicaments contenant de telles preparations
US5804374A (en) 1980-12-05 1998-09-08 Massachusetts Insti. Technology Nuclear factors associates with transcriptional regulation
FR2553287B1 (fr) 1983-10-18 1986-09-12 Choay Sa Compositions a base de mucopolysaccharides ou d'oligosaccharides, notamment a base de fractions ou fragments d'heparine, appropriees au traitement de desordres de la proliferation cellulaire
DE3422518A1 (de) 1984-06-16 1985-12-19 B. Braun Melsungen Ag, 3508 Melsungen Heparin-derivate, verfahren zu ihrer herstellung, diese enthaltende arzneimittel und ihre verwendung bei der behandlung von fettstoffwechselstoerungen
FR2584606A1 (fr) 1985-07-12 1987-01-16 Dropic Utilisation de poly- et oligosaccharides pour l'obtention de medicaments actifs dans les pathologies du tissu conjonctif
US5380716A (en) 1988-12-15 1995-01-10 Glycomed, Inc. Sulfated polysaccharides as inhibitors of smooth muscle cell proliferation
IT1234826B (it) 1989-01-30 1992-05-29 Alfa Wassermann Spa Derivati eparinici e procedimento per la loro preparazione
US5399493A (en) 1989-06-15 1995-03-21 The Regents Of The University Of Michigan Methods and compositions for the optimization of human hematopoietic progenitor cell cultures
AU7681091A (en) 1990-04-05 1991-10-30 John R Hoidal Method and medicament for prevention or medication of human leucocyte elastase-mediated pulmonary diseases
US5250519A (en) 1991-03-29 1993-10-05 Glycomed Incorporated Non-anticoagulant heparin derivatives
IT1254216B (it) 1992-02-25 1995-09-14 Opocrin Spa Derivati polisaccaridici di eparina, eparan solfato, loro frazioni e frammenti, procedimento per la loro preparazione e composizioni farmaceutiche che li contengono
WO1993019734A1 (en) 1992-04-02 1993-10-14 Baker Norton Pharmaceuticals, Inc. Method and composition for treating antigen-induced and exercise-induced asthma
US5668118A (en) 1992-07-24 1997-09-16 Cavalier Pharmaceuticals Method of synthesis of 2-O-desulfated Heparin and use thereof for inhibition of elastase and Cathepspin G
US5306724A (en) 1992-08-17 1994-04-26 Clintec Nutrition Company Method for preventing and treating atherosclerosis
GB2270841A (en) 1992-09-09 1994-03-30 Merck & Co Inc Compositions for Treating vascular restenosis
US5696100A (en) * 1992-12-22 1997-12-09 Glycomed Incorporated Method for controlling O-desulfation of heparin and compositions produced thereby
US5296471A (en) 1992-12-22 1994-03-22 Glycomed Incorporated Method for controlling o-desulfation of heparin and compositions produced thereby
AU6246394A (en) 1993-02-22 1994-09-14 Cavalier Pharmaceuticals, Inc. Use of heparin to inhibit interleukin-8
SE9302135D0 (sv) 1993-06-18 1993-06-18 Kabi Pharmacia Ab New pharmaceutical composition
US5840707A (en) 1993-10-04 1998-11-24 Albany Medical College Stabilizing and delivery means of biological molecules
US5994318A (en) 1993-10-04 1999-11-30 Albany Medical College Cochleate delivery vehicles
JPH09512822A (ja) 1994-05-06 1997-12-22 グリコメド・インコーポレイテッド Ｏ−脱硫酸化ヘパリン誘導体とその製造法および使用
US5804560A (en) 1995-01-06 1998-09-08 Sibia Neurosciences, Inc. Peptide and peptide analog protease inhibitors
WO1998004133A1 (en) 1996-07-29 1998-02-05 Cavalier Pharmaceuticals Methods of treating asthma with o-desulfated heparin
US6154502A (en) 1996-08-22 2000-11-28 Intel Corporation Signal constellation slicer
US7258857B2 (en) 1996-11-22 2007-08-21 The Trustees Of Columbia University In The City Of New York Rage-related methods for treating inflammation
DE69814618T2 (de) 1997-02-15 2004-03-25 Millenium Pharmaceuticals, Inc., Cambridge Behandlung von infarkten durch inhibierung von nf-kappab
DE69821932T2 (de) 1997-05-30 2004-12-16 Arch Development Corp., Chicago P-selectin translokation ins vaskulare epitheliale lumen durch ionisierende strahlung
US6406862B1 (en) 1998-10-06 2002-06-18 The United States Of America As Represented By The Secretary Of The Army Dip-stick assay for C-reactive protein
ATE320263T1 (de) 1998-11-13 2006-04-15 Lilly Co Eli Verwendung von menschliche protein c zur herstellung eines arzneimittels zur behandlung von heparininduzierter thrombozytopenie
US20030083231A1 (en) * 1998-11-24 2003-05-01 Ahlem Clarence N. Blood cell deficiency treatment method
US6153217A (en) 1999-01-22 2000-11-28 Biodelivery Sciences, Inc. Nanocochleate formulations, process of preparation and method of delivery of pharmaceutical agents
US6514502B1 (en) 1999-01-26 2003-02-04 Schering-Plough Veterinary Corporation Propagation of bovine cononavirus in chinese hamster ovary cells
AU763042B2 (en) 1999-09-13 2003-07-10 Charlotte-Mecklenburg Hospital Authority Method of inhibiting NF-kappaB with heparin
US7781416B2 (en) 2000-01-25 2010-08-24 Sigma-Tau Research Switzerland S.A. Derivatives of partially desulphated glycosaminoglycans as heparanase inhibitors, endowed with antiangiogenic activity and devoid of anticoagulating effect
US6489311B1 (en) 2000-05-02 2002-12-03 Charlotte-Mecklenburg Hospital Authoirty Method for the prevention of apoptosis
EE200300510A (et) * 2001-04-18 2004-02-16 Prometic Biosciences Inc. Keskmise pikkusega ahelaga rasvhapped, glütseriidid ja nende analoogid kui neutrofiilide ellujäämis- ja aktiveerimisfaktorid
AU2003230985A1 (en) 2002-04-18 2003-11-03 Stephen H. Embury Method and composition for preventing pain in sickle cell patients
JP2005535665A (ja) 2002-07-09 2005-11-24 ザ スクリプス リサーチ インスティテュート 虚血および再灌流損傷を防止する方法
US8404716B2 (en) 2002-10-15 2013-03-26 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
AU2003293122A1 (en) 2002-11-27 2004-06-23 Massachusetts Institute Of Technology Methods for synthesizing polysaccharides
US20040180812A1 (en) 2002-12-13 2004-09-16 Technology Center Methods of treating and preventing proliferative disease
EP1635823A1 (en) 2003-05-20 2006-03-22 TransTech Pharma Inc. Rage antagonists as agents to reverse amyloidosis and diseases associated therewith
WO2005089365A2 (en) 2004-03-16 2005-09-29 The General Hospital Corporation Treatment and prevention of abnormal cellular proliferation
CA2564542C (en) * 2004-04-22 2012-11-27 Celator Pharmaceuticals, Inc. Combination formulations of anthracycline agents and cytidine analogs
US20050261241A1 (en) 2004-05-19 2005-11-24 Celsus Biopharmaceuticals, Inc. Use of dermatan sulfates and/or desulfated heparins to treat or prevent heparinoid-induced autoimmune responses
US20050282775A1 (en) 2004-06-16 2005-12-22 Paringenix, Inc. Method and medicament for sulfated polysaccharide treatment of inflammation without inducing platelet activation and heparin-induced thrombocytopenia syndrome
US7468358B2 (en) 2004-06-16 2008-12-23 Paringenix, Inc. Method and medicament for sulfated polysaccharide treatment of heparin-induced thrombocytopenia (HIT) syndrome
US20060040896A1 (en) 2004-08-18 2006-02-23 Paringenix, Inc. Method and medicament for anticoagulation using a sulfated polysaccharide with enhanced anti-inflammatory activity
JP2006076968A (ja) 2004-09-10 2006-03-23 Seikagaku Kogyo Co Ltd 生理活性分子含有架橋ヘパリンゲル組成物
MX2008000974A (es) 2005-07-22 2008-03-27 Univ California Composiciones de heparina e inhibicion de selectina.
WO2007019554A2 (en) 2005-08-08 2007-02-15 Momenta Pharmaceuticals, Inc. Polysaccharides for delivery of active agents
WO2007040105A1 (ja) 2005-09-30 2007-04-12 Takara Bio Inc. Ｔ細胞集団の製造方法
EA200870059A1 (ru) 2005-12-16 2008-12-30 ДиЭнПи КЭНАДА ИНК. Производные хитина для применения при гиперлипидемии
WO2007115372A1 (en) 2006-04-10 2007-10-18 Monash University A method of modulating beta-amyloid peptide production
US20100003226A1 (en) 2006-07-26 2010-01-07 Intrexon Corporation Methods and Compositions for Treating Disease
JP2010504356A (ja) 2006-09-20 2010-02-12 ザ ジョンズ ホプキンス ユニバーシティー 抗ｂ７−ｈ１抗体を用いた癌及び感染性疾患の組合せ療法
WO2008106584A1 (en) 2007-02-28 2008-09-04 Paringenix, Inc. O-desulfated heparins treating acute exacerbations of chronic obstructive pulmonary disease
PT2155188E (pt) * 2007-06-01 2013-12-19 Abraxis Bioscience Llc Métodos e composições para o tratamento de cancro recorrente
JP2010534672A (ja) 2007-07-23 2010-11-11 ユニバーシティ オブ ユタ リサーチ ファウンデーション 終末糖化産物受容体（ｒａｇｅ）の連結を阻止するための方法
US8569262B2 (en) 2007-11-02 2013-10-29 Momenta Pharmaceuticals, Inc. Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
WO2009117677A2 (en) 2008-03-21 2009-09-24 University Of Utah Research Foundation Methods for controlling intracellular calcium levels associated with an ischemic event
JP5758797B2 (ja) 2008-04-04 2015-08-05 ユニバーシティ・オブ・ユタ・リサーチ・ファウンデイション アルキル化半合成グリコサミノグリカンエーテルならびにその製造および使用方法
US8476249B2 (en) * 2009-05-07 2013-07-02 Glaxosmithkline Llc Method of treating thrombocytopenia
US20130034534A1 (en) 2009-09-29 2013-02-07 Philipp Kroneberg Method for treatment of patients with cystic fibrosis
AU2011226755A1 (en) 2010-03-12 2012-10-04 The Australian National University Heparan sulfate replacement therapy
AU2011231978B2 (en) 2010-03-24 2014-12-18 Centre National De La Recherche Scientifique (Cnrs) Prophylaxis of colorectal and gastrointestinal cancer
BR112012033548A2 (pt) 2010-06-28 2017-06-20 Stemtech Int Inc métodos e composições para melhorar a mobilização de células-tronco
WO2012106299A1 (en) * 2011-01-31 2012-08-09 Celgene Corporation Pharmaceutical compositions of cytidine analogs and methods of use thereof
US20120196828A1 (en) 2011-02-01 2012-08-02 Paringenix, Inc. Sensitization of cancer cells to treatment
WO2013016181A1 (en) 2011-07-22 2013-01-31 Paringenix, Inc. Compositions and methods for anti-coagulation
US20160109459A1 (en) 2012-05-01 2016-04-21 Duke University Compositions And Methods For Heparan Sulfate As A Biomarker For Transplant Rejection
BR112014028094B1 (pt) 2012-05-09 2022-03-03 Cantex Pharmaceuticals, Inc Uso de um heparinoide interagindo com fator de plaqueta 4
EP2961828A4 (en) 2013-02-28 2016-08-03 Harvard College COMPOSITIONS AND METHOD FOR MOBILIZING STEM CELLS
CA2928585A1 (en) 2013-10-22 2015-04-30 Cantex Pharmaceuticals, Inc. Methods of treating and preventing radiation damage
WO2015061604A1 (en) 2013-10-24 2015-04-30 Thomas Kennedy Treating bacterial infections of the lung
US20170096549A1 (en) 2014-03-17 2017-04-06 Cantex Pharmaceuticals, Inc. Multivalent cation formulations of partially desulfated heparins
WO2016133910A1 (en) 2015-02-17 2016-08-25 Cantex Pharmaceuticals, Inc. Treatment of cancers and hematopoietic stem cell disorders privileged by cxcl12-cxcr4 interaction
EP3258940A1 (en) 2015-02-17 2017-12-27 Cantex Pharmaceuticals, Inc. Adoptive cell transfer methods
US20170106011A1 (en) 2015-10-20 2017-04-20 Cantex Pharmaceuticals, Inc. Methods of treating traumatic brain injury and sequelae
WO2017123549A1 (en) 2016-01-11 2017-07-20 Cantex Pharmaceuticals, Inc. Methods of treating or preventing graft-versus-host disease using hmgb1-interacting heparinoids

Also Published As

Publication number Publication date
BR112014028094B1 (pt) 2022-03-03
JP6448694B2 (ja) 2019-01-09
JP2017105850A (ja) 2017-06-15
EP2846809B1 (en) 2020-10-14
CA2872855C (en) 2021-07-27
ES2848050T3 (es) 2021-08-05
EP2846809A1 (en) 2015-03-18
IL235593A0 (en) 2015-01-29
AU2013260101A1 (en) 2014-12-18
KR102165348B1 (ko) 2020-10-14
CL2014003017A1 (es) 2015-07-10
US8734804B2 (en) 2014-05-27
SG10201914117QA (en) 2020-02-27
US20130303481A1 (en) 2013-11-14
WO2013169355A1 (en) 2013-11-14
MX370567B (es) 2019-12-17
JP6177885B2 (ja) 2017-08-09
US20200038431A1 (en) 2020-02-06
US20180296590A1 (en) 2018-10-18
KR102452803B1 (ko) 2022-10-07
HUE053247T2 (hu) 2021-06-28
EP2846809A4 (en) 2015-12-30
US20130323230A1 (en) 2013-12-05
CN104411316A (zh) 2015-03-11
LT2846809T (lt) 2021-01-25
JP2019026647A (ja) 2019-02-21
KR20150023361A (ko) 2015-03-05
CN104411316B (zh) 2018-05-01
PL2846809T3 (pl) 2021-07-26
MX2019009437A (es) 2019-10-02
IL235593B (en) 2019-06-30
EA201492052A1 (ru) 2015-08-31
EA029382B1 (ru) 2018-03-30
JP2015521176A (ja) 2015-07-27
AU2013260101B2 (en) 2016-10-27
DK2846809T3 (da) 2021-01-18
US11229664B2 (en) 2022-01-25
MX2014013633A (es) 2015-07-06
US9271999B2 (en) 2016-03-01
JP6726252B2 (ja) 2020-07-22
SG11201407340YA (en) 2014-12-30
BR112014028094A2 (pt) 2020-06-30
CA2872855A1 (en) 2013-11-14
PT2846809T (pt) 2021-02-05
US20220354882A1 (en) 2022-11-10
HK1207574A1 (en) 2016-02-05
KR20200118510A (ko) 2020-10-15
CN108498532B (zh) 2021-07-23
SG10201603059YA (en) 2016-05-30
CN108498532A (zh) 2018-09-07
EP3785720A1 (en) 2021-03-03
US20160213706A1 (en) 2016-07-28
CA3122808A1 (en) 2013-11-14
CN113521093A (zh) 2021-10-22

Similar Documents

Publication Publication Date Title
CL2021000008A1 (es) Uso de un heparinoide para el tratamiento del cáncer (divisional de la solicitud n° 201403017)
CL2014002873A1 (es) Compuestos derivados de pirimidin-amina o triazin-amina, inhibidores de adn-pk; composicion farmaceutica; y su uso para el tratamiento del cancer.
CL2017003024A1 (es) Tratamiento para el cancer a traves de la manipulación de microflora comensal
UY34657A (es) ?derivados macrocíclicos para el tratamiento de enfermedades?.
NI201600144A (es) Derivados de quinoxalina utiles como moduladores del fgfr cinasa
CL2012003415A1 (es) Compuestos derivados de 2-oxo-piperidina y 1,1-dioxido-tiazina, inhibidores de mdm2; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer .
EA201400178A1 (ru) Лечение рака молочной железы
CL2015000711A1 (es) Compuestos derivados de bis(fluoroalquil)-1,4-benzodiazepinona como inhibidores de notch; composicion farmaceutica y uso en el tratamiento del cancer.
CL2015000873A1 (es) Métodos para el tratamiento del síndrome de alport.
LT3026064T (lt) Antikūnai, skirti vėžio gydymui, ekspresuojantys klaudiną 6
UY34566A (es) 1,4?dihidropirimidinas 4,4?disustituidas y su uso como medicamentos para el tratamiento de la hepatitis b
BR112015011112A2 (pt) composto oligomérico, oligômero, composição farmacêutica, uso do composto oligomérico, método de síntese de um composto oligomérico e método de tratamento de uma doença.
CL2014001858A1 (es) Compuestos derivados de pirrolidina-2-carboxamidas sustituidas, antagonistas de mdm2; composicion farmacetica; y su uso en el tratamiento o profilaxis del cancer.
LT2984166T (lt) Kompozicijos, skirtos mpsi gydymui
ES2765949T8 (es) Terapia que involucra anticuerpos contra la claudina 18.2 para el tratamiento del cáncer
CL2015002591A1 (es) Entidades químicas.
BR112014005091A2 (pt) composição farmacêutica para o tratamento do câncer compreendendo conjugado de interferon alfa
BR112014030416A2 (pt) composto, métodos para a inibição da tankyrase 1 e para o tratamento do câncer, utilização de um composto, composição e invenção.
CL2015001202A1 (es) Compuestos derivados de oxazolidin-2-ona-pirimidina; composicion y combinacion farmaceutica y uso en el tratamiento del cancer.
BRPI1007995A2 (pt) orto-aminoamidas para o tratamento de cãncer.
CL2015000926A1 (es) Proceso para la elaboración de compuestos para el tratamiento del cancer derivados de azetidin-1-il-metanona y compuestos intermediarios.
AR125920A2 (es) Composiciones que comprenden vortioxetina y donepezil
CL2012003322A1 (es) Compuestos derivados de benzamida sustituidas; composicion farmacéutica; y uso en el tratamiento del cancer.
BR112015002824A2 (pt) composto, uso de um composto, composição farmacêutica, e, produto farmacêutico de combinação.
PT2928477T (pt) Utilização do inibidor da telomerase imetelstat para o tratamento de mielofibrose.